Therefore, we hypothesized that ATRA treatment would not only reduce the expression of stemness markers (SOX2, NES) but also concurrently decrease the transcript and protein levels of the chemoresistance gene MGMT in established human GBM cell lines cultured under neurosphere conditions. The gene discussed is SOX2; the disease is glioblastoma.